Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression Diabetic kidney disease (DKD) is a major cause of chronic kidney disease (CKD) and increases the risk of cardiovascular events. The pathogenesis of DKD involves hemodynamic, inflammatory, and metabolic factors that converge on the fibrotic pathway. Genetic predisposition and unhealthy lifestyles contribute to DKD development and progression. Despite the use of angiotensin receptor blockers (ARBs)/angiotensin converting enzyme inhibitors (ACEI), sodium-glucose cotransporter 2 (SGLT2) inhibitors, and nonsteroidal mineralocorticoid receptor antagonists (NS-MRAs), current therapies fail to effectively halt DKD progression. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) show promise as renal protectors. Other agents, including pentoxifylline (PTF), selonsertib, and baricitinib, also hold potential due to their anti-inflammatory and antifibrotic properties. Multidisciplinary treatment, including lifestyle modifications and drug therapy, can slow DKD progression. Combining multiple drugs is recommended over single-use drugs. Inflammatory and fibrotic factors, including IL-1, MCP-1, MMP-9, CTGF, TNF-α, and TGF-β1, as well as long non-coding RNAs (lncRNAs), serve as diagnostic biomarkers and therapeutic targets. The review discusses the mechanisms and current therapies of DKD, emphasizing the need for further research to optimize management. Targeting mechanisms such as HIF inhibitors, AGE inhibitors, and epigenetic modifications are proposed as future therapeutic strategies. The review highlights the importance of early diagnosis and risk factor management to improve cost-effectiveness and outcomes in DKD.Recent Advances in the Management of Diabetic Kidney Disease: Slowing Progression Diabetic kidney disease (DKD) is a major cause of chronic kidney disease (CKD) and increases the risk of cardiovascular events. The pathogenesis of DKD involves hemodynamic, inflammatory, and metabolic factors that converge on the fibrotic pathway. Genetic predisposition and unhealthy lifestyles contribute to DKD development and progression. Despite the use of angiotensin receptor blockers (ARBs)/angiotensin converting enzyme inhibitors (ACEI), sodium-glucose cotransporter 2 (SGLT2) inhibitors, and nonsteroidal mineralocorticoid receptor antagonists (NS-MRAs), current therapies fail to effectively halt DKD progression. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) show promise as renal protectors. Other agents, including pentoxifylline (PTF), selonsertib, and baricitinib, also hold potential due to their anti-inflammatory and antifibrotic properties. Multidisciplinary treatment, including lifestyle modifications and drug therapy, can slow DKD progression. Combining multiple drugs is recommended over single-use drugs. Inflammatory and fibrotic factors, including IL-1, MCP-1, MMP-9, CTGF, TNF-α, and TGF-β1, as well as long non-coding RNAs (lncRNAs), serve as diagnostic biomarkers and therapeutic targets. The review discusses the mechanisms and current therapies of DKD, emphasizing the need for further research to optimize management. Targeting mechanisms such as HIF inhibitors, AGE inhibitors, and epigenetic modifications are proposed as future therapeutic strategies. The review highlights the importance of early diagnosis and risk factor management to improve cost-effectiveness and outcomes in DKD.